Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
CKD · dialysis · CRRT
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney dosing for each component (single-agent) is shown under Component information.
Kidney-specific guidance from renalcarematters.com: in preparation.
Parenteral nutrition · CKD · AKI · KRT
Parenteral nutrition: kidney notes
Brand-specific kidney notes for the parenteral nutrition products filed under this generic: composition from the manufacturer SmPC or package insert, its kidney-related text, and how the product fits the guideline. Sources are listed under References.
Nutriflex Lipid Peri (B. Braun Melsungen AG) is a lower-osmolarity three-chamber bag of amino acids with electrolytes, glucose and a lipid emulsion for peripheral infusion. Philippine registrations: 1250, 1875 and 2500 ml bags. It is a standard formula containing potassium and phosphate.
Composition from the Irish (EU) SmPC of NuTRIflex Lipid peri; the Philippine package insert was not available to compare.
Composition from the cited manufacturer SmPC/package insert; values independently re-checked November 17, 2026.
Dose and rate limits
Adults and adolescents from 14 years: maximum daily dose 40 ml/kg body weight; maximum infusion rate 2.5 ml/kg/hour (SmPC 4.2).
Kidney notes
Contraindicated in "severe renal insufficiency in absence of renal replacement therapy" and in disturbances of the electrolyte and fluid balance (SmPC 4.3).
Give with caution to patients with impaired cardiac or renal function; experience in renal failure is limited (SmPC 4.4).
Check serum electrolytes, water balance, acid-base balance and renal function; take care when giving other solutions that contain phosphate, zinc, magnesium or calcium (SmPC 4.4).
How it fits the ESPEN 2021 kidney nutrition guideline
ESPEN 2021 Recommendation 18 (Grade of recommendation 0 – Consensus (82.6% agreement)): protein intakes that may be prescribed are 0.6–0.8 g/kg body weight (BW)/d for a hospitalized patient with CKD without acute/critical illness; 1.2 g/kg BW/d with CKD and KF on conventional intermittent chronic KRT without acute/critical illness; 0.8–1.0 g/kg BW/d with AKI or AKI on CKD without acute/critical illness; start with 1 g/kg BW/day and gradually increase up to 1.3 g/kg BW/d if tolerated with acute/critical illness not on KRT; 1.3–1.5 g/kg/d for critically ill patients on conventional intermittent KRT; and 1.5 g/kg/d up to 1.7 g/kg/d for critically ill patients on continuous KRT (CKRT) or prolonged intermittent KRT (PIKRT). "If available, the pre-hospitalization body weight or usual body weight may be preferred over the ideal BW. Actual BW should not be considered for a protein prescription." (AKI, acute kidney injury.)
ESPEN 2021 Recommendation 25: "The choice of the most appropriate EN or PN formula should be made based on the calorie and protein ratio to provide the most accurate dosing in clinical practice." Grade of recommendation B – Strong consensus (91.3% agreement). (PN, parenteral nutrition.)
ESPEN 2021 Recommendation 24: "No disease-specific enteral nor parenteral formula oriented for patients with reduced kidney function should be routinely utilized in every patient with AKI, AKI on CKD, or CKD with KF in comparison to conventional formulas. Instead, their use is to be individualized (see recommendation 26)." Grade of recommendation B – Consensus (87.5% agreement).
ESPEN 2021 Recommendation 26: "In selected patients with electrolyte and fluid imbalances, concentrated “renal” EN or PN formulas with lower electrolyte content may be preferred over standard formulas." Grade of recommendation GPP – Strong consensus (95.7% agreement). (GPP, good practice point.)
ESPEN 2021 Recommendation 31: "Electrolytes abnormalities are common in patients with AKI, AKI on CKD, or CKD with KF receiving KRT and shall be closely monitored." Grade of recommendation A – Strong consensus (100% agreement).
ESPEN 2021 Recommendation 29: "Serum glucose levels shall be maintained between 140–180 mg/dl in hospitalized patients with AKI, AKI on CKD, or CKD with KF." Grade of recommendation A – Strong consensus (95.5% agreement). Recommendation 30: "Tight glucose control (80–110 mg/dl) shall not be pursued because of the increased risk of hypoglycemia." Grade of recommendation A – Strong consensus (100% agreement).
ESPEN 2021 Recommendation 14: "For patients undergoing KRT, the total energy provision by additional calories given in the form of citrate, lactate, and glucose from dialysis/hemofiltration solutions should be included in the calculations to determine the total daily energy provision to avoid overfeeding." Grade of recommendation B – Strong consensus (100% agreement). (KRT, kidney replacement therapy.)
ESPEN 2021 Recommendation 4: "Intradialytic parenteral nutrition (IDPN) shall be applied in malnourished non-critically ill hospitalized patients with CKD and KF on hemodialysis, or the same patients if at risk of malnutrition that fail to respond or do not tolerate ONS or EN." Grade of recommendation A – Strong consensus (91.7% agreement). (CKD, chronic kidney disease; KF, kidney failure; ONS, oral nutritional supplements; EN, enteral nutrition.)
Bottom line
A standard peripheral three-chamber bag. In severe renal insufficiency it needs renal replacement therapy; count its potassium and phosphate and its volume, and monitor electrolytes and renal function.
renalcarematters.com notes, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Check the current Philippine package insert before use. renalcarematters.com, reviewed
Kidney notes: Nutriflex Lipid Special
Nutriflex Lipid Special (B. Braun Melsungen AG) is a high-concentration three-chamber bag of amino acids with electrolytes, glucose and a lipid emulsion for parenteral nutrition. Philippine registrations: 625, 1250, 1875 and 2500 ml bags. It is a standard formula, higher in protein per ml, containing potassium and phosphate.
Composition
Per presentation
625 ml bag
1250 ml bag
1875 ml bag
2500 ml bag
Amino acids (g)
35.9
71.8
107.7
143.6
Nitrogen (g)
5
10
15
20
Lipid (g)
25
50
75
100
Carbohydrate (glucose) (g)
90
180
270
360
Energy, total (kcal)
740
1475
2215
2950
Energy, non-protein (kcal)
600
1195
1795
2390
Sodium (mmol)
33.5
67
100.5
134
Potassium (mmol)
23.5
47
70.5
94
Magnesium (mmol)
2.65
5.3
7.95
10.6
Calcium (mmol)
2.65
5.3
7.95
10.6
Phosphate (mmol)
10
20
30
40
Zinc (mmol)
0.02
0.04
0.06
0.08
Chloride (mmol)
30
60
90
120
Acetate (mmol)
30
60
90
120
Osmolality 2090 mOsm/kg (SmPC; same in the BPOM product information).
Composition from an Irish SmPC last revised April 2011 and Indonesian BPOM product information last revised September 2007; check against the current Philippine package insert.
Composition from the cited manufacturer SmPC (2011) and cross-checked against the Indonesian BPOM product information (2007): all values for the 1250, 1875 and 2500 ml bags agree. The 625 ml bag appears only in the SmPC (its values are exactly half of the 1250 ml bag).
Dose and rate limits
Adults: maximum infusion rate 1.7 ml/kg body weight per hour; maximum daily dose 35 ml/kg body weight (SmPC 4.2; same in the BPOM product information).
Kidney notes
Contraindicated in severe renal insufficiency, hyperkalemia, hypernatremia, disturbances of the electrolyte and fluid balance and states of hyperhydration (SmPC 4.3). Both the 2011 SmPC and the 2007 BPOM product information list severe renal insufficiency as a contraindication with no exception for patients on dialysis; check the current Philippine package insert for its wording.
Give with caution to patients with impaired cardiac or renal function; correct hyperkalemia and acidosis before starting; monitor serum electrolytes, water balance and acid-base balance (SmPC 4.4).
How it fits the ESPEN 2021 kidney nutrition guideline
ESPEN 2021 Recommendation 18 (Grade of recommendation 0 – Consensus (82.6% agreement)): protein intakes that may be prescribed are 0.6–0.8 g/kg body weight (BW)/d for a hospitalized patient with CKD without acute/critical illness; 1.2 g/kg BW/d with CKD and KF on conventional intermittent chronic KRT without acute/critical illness; 0.8–1.0 g/kg BW/d with AKI or AKI on CKD without acute/critical illness; start with 1 g/kg BW/day and gradually increase up to 1.3 g/kg BW/d if tolerated with acute/critical illness not on KRT; 1.3–1.5 g/kg/d for critically ill patients on conventional intermittent KRT; and 1.5 g/kg/d up to 1.7 g/kg/d for critically ill patients on continuous KRT (CKRT) or prolonged intermittent KRT (PIKRT). "If available, the pre-hospitalization body weight or usual body weight may be preferred over the ideal BW. Actual BW should not be considered for a protein prescription." (AKI, acute kidney injury.)
ESPEN 2021 Recommendation 25: "The choice of the most appropriate EN or PN formula should be made based on the calorie and protein ratio to provide the most accurate dosing in clinical practice." Grade of recommendation B – Strong consensus (91.3% agreement). (PN, parenteral nutrition.)
ESPEN 2021 Recommendation 24: "No disease-specific enteral nor parenteral formula oriented for patients with reduced kidney function should be routinely utilized in every patient with AKI, AKI on CKD, or CKD with KF in comparison to conventional formulas. Instead, their use is to be individualized (see recommendation 26)." Grade of recommendation B – Consensus (87.5% agreement).
ESPEN 2021 Recommendation 26: "In selected patients with electrolyte and fluid imbalances, concentrated “renal” EN or PN formulas with lower electrolyte content may be preferred over standard formulas." Grade of recommendation GPP – Strong consensus (95.7% agreement). (GPP, good practice point.)
ESPEN 2021 Recommendation 31: "Electrolytes abnormalities are common in patients with AKI, AKI on CKD, or CKD with KF receiving KRT and shall be closely monitored." Grade of recommendation A – Strong consensus (100% agreement).
ESPEN 2021 Recommendation 29: "Serum glucose levels shall be maintained between 140–180 mg/dl in hospitalized patients with AKI, AKI on CKD, or CKD with KF." Grade of recommendation A – Strong consensus (95.5% agreement). Recommendation 30: "Tight glucose control (80–110 mg/dl) shall not be pursued because of the increased risk of hypoglycemia." Grade of recommendation A – Strong consensus (100% agreement).
ESPEN 2021 Recommendation 14: "For patients undergoing KRT, the total energy provision by additional calories given in the form of citrate, lactate, and glucose from dialysis/hemofiltration solutions should be included in the calculations to determine the total daily energy provision to avoid overfeeding." Grade of recommendation B – Strong consensus (100% agreement). (KRT, kidney replacement therapy.)
ESPEN 2021 Recommendation 4: "Intradialytic parenteral nutrition (IDPN) shall be applied in malnourished non-critically ill hospitalized patients with CKD and KF on hemodialysis, or the same patients if at risk of malnutrition that fail to respond or do not tolerate ONS or EN." Grade of recommendation A – Strong consensus (91.7% agreement). (CKD, chronic kidney disease; KF, kidney failure; ONS, oral nutritional supplements; EN, enteral nutrition.)
Bottom line
A concentrated standard central bag that delivers more protein per ml, which can help when fluid must be limited, but it carries 47 mmol potassium and 20 mmol phosphate per 1250 ml. The available SmPC lists severe renal insufficiency as a contraindication without a dialysis exception: confirm the current Philippine insert before using it in kidney failure.
renalcarematters.com notes, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Check the current Philippine package insert before use. renalcarematters.com, reviewed
Kidney notes: Nutriflex Omega Peri
Nutriflex Omega Peri (B. Braun Melsungen AG) is a lower-osmolarity three-chamber bag of amino acids with electrolytes, glucose and a lipid emulsion containing medium-chain triglycerides, soybean oil and omega-3-acid triglycerides, for peripheral infusion. Philippine registrations: 1.25, 1.875 and 2.5 L bags. It is a standard formula containing potassium and phosphate.
Source is the Irish SmPC of the same B. Braun product sold in Ireland as Omeflex peri; its 1250 ml column (955 kcal, 40 g amino acids, 50 g lipid, 80 g carbohydrate) matches the Philippine registration exactly. Confirm against the Philippine package insert.
Composition from the cited manufacturer SmPC/package insert; values independently re-checked November 17, 2026.
Dose and rate limits
Adults: maximum daily dose 40 ml/kg body weight; maximum infusion rate 2.0 ml/kg/hour (SmPC 4.2).
Kidney notes
Contraindicated in "severe renal insufficiency in absence of renal replacement therapy" and in disturbances of the electrolyte and fluid balance (SmPC 4.3).
Give with caution to patients with impaired cardiac or renal function; experience in renal failure is limited (SmPC 4.4).
Use caution with drugs that raise serum potassium, such as ACE inhibitors, angiotensin receptor blockers and potassium-sparing diuretics (SmPC 4.5).
Refeeding may cause hypokalemia, hypophosphatemia and hypomagnesemia; close monitoring of serum electrolytes is required, with checks of water balance, acid-base balance and renal function (SmPC 4.4).
How it fits the ESPEN 2021 kidney nutrition guideline
ESPEN 2021 Recommendation 18 (Grade of recommendation 0 – Consensus (82.6% agreement)): protein intakes that may be prescribed are 0.6–0.8 g/kg body weight (BW)/d for a hospitalized patient with CKD without acute/critical illness; 1.2 g/kg BW/d with CKD and KF on conventional intermittent chronic KRT without acute/critical illness; 0.8–1.0 g/kg BW/d with AKI or AKI on CKD without acute/critical illness; start with 1 g/kg BW/day and gradually increase up to 1.3 g/kg BW/d if tolerated with acute/critical illness not on KRT; 1.3–1.5 g/kg/d for critically ill patients on conventional intermittent KRT; and 1.5 g/kg/d up to 1.7 g/kg/d for critically ill patients on continuous KRT (CKRT) or prolonged intermittent KRT (PIKRT). "If available, the pre-hospitalization body weight or usual body weight may be preferred over the ideal BW. Actual BW should not be considered for a protein prescription." (AKI, acute kidney injury.)
ESPEN 2021 Recommendation 25: "The choice of the most appropriate EN or PN formula should be made based on the calorie and protein ratio to provide the most accurate dosing in clinical practice." Grade of recommendation B – Strong consensus (91.3% agreement). (PN, parenteral nutrition.)
ESPEN 2021 Recommendation 24: "No disease-specific enteral nor parenteral formula oriented for patients with reduced kidney function should be routinely utilized in every patient with AKI, AKI on CKD, or CKD with KF in comparison to conventional formulas. Instead, their use is to be individualized (see recommendation 26)." Grade of recommendation B – Consensus (87.5% agreement).
ESPEN 2021 Recommendation 26: "In selected patients with electrolyte and fluid imbalances, concentrated “renal” EN or PN formulas with lower electrolyte content may be preferred over standard formulas." Grade of recommendation GPP – Strong consensus (95.7% agreement). (GPP, good practice point.)
ESPEN 2021 Recommendation 31: "Electrolytes abnormalities are common in patients with AKI, AKI on CKD, or CKD with KF receiving KRT and shall be closely monitored." Grade of recommendation A – Strong consensus (100% agreement).
ESPEN 2021 Recommendation 29: "Serum glucose levels shall be maintained between 140–180 mg/dl in hospitalized patients with AKI, AKI on CKD, or CKD with KF." Grade of recommendation A – Strong consensus (95.5% agreement). Recommendation 30: "Tight glucose control (80–110 mg/dl) shall not be pursued because of the increased risk of hypoglycemia." Grade of recommendation A – Strong consensus (100% agreement).
ESPEN 2021 Recommendation 14: "For patients undergoing KRT, the total energy provision by additional calories given in the form of citrate, lactate, and glucose from dialysis/hemofiltration solutions should be included in the calculations to determine the total daily energy provision to avoid overfeeding." Grade of recommendation B – Strong consensus (100% agreement). (KRT, kidney replacement therapy.)
ESPEN 2021 Recommendation 4: "Intradialytic parenteral nutrition (IDPN) shall be applied in malnourished non-critically ill hospitalized patients with CKD and KF on hemodialysis, or the same patients if at risk of malnutrition that fail to respond or do not tolerate ONS or EN." Grade of recommendation A – Strong consensus (91.7% agreement). (CKD, chronic kidney disease; KF, kidney failure; ONS, oral nutritional supplements; EN, enteral nutrition.)
ESPEN 2021 Recommendation 27: "There is not enough evidence to support the routine use of omega-3 polyunsaturated fatty acids (PUFA) supplements or PN solutions enriched with omega-3 PUFA in hospitalized patients with AKI, AKI on CKD or CKD with KF." Grade of recommendation GPP – Strong consensus (95.8% agreement).
Bottom line
A standard peripheral bag with an omega-3-containing lipid; ESPEN finds the evidence insufficient to use omega-3-enriched PN routinely in kidney disease. In severe renal insufficiency it needs renal replacement therapy; count its potassium and phosphate, and watch potassium closely with RAAS blockers.
renalcarematters.com notes, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Check the current Philippine package insert before use. renalcarematters.com, reviewed
Dosage forms
Philippines
Emulsion for intravenous infusion
Emulsion for injection for i.v. infusion: 40 g, Lipid 50 g, Carbohydrate 80 g
Philippine products
Registered products in the Philippines
3 products registered with the Food and Drug Administration (FDA) Philippines list
Amino acids + Glucose + Lipids as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
955 kcal, Amino acid 40 g, Lipid 50 g, Carbohydrate 80 g Emulsion for Injection for I.V. InfusionThree-Chamber Plastic Bag Made of a Transparent, Colorless Multi-Layer Polymer Film x 1.25 L, 1.875 L and 2.5 L (Bag of 1's & Box of 5's)
Rx
B. Braun Melsungen AGGermany
B. Braun Medical Supplies, Incorporated
DR-XY49834
Nov 5, 2031
No products match these filters.
Source: FDA Philippines product registration database. "Valid until" is the registration validity date
listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Fiaccadori, E., Sabatino, A., Barazzoni, R., Carrero, J. J., Cupisti, A., De Waele, E., Jonckheer, J., Singer, P., & Cuerda, C. (2021). ESPEN guideline on clinical nutrition in hospitalized patients with acute or chronic kidney disease. Clinical Nutrition, 40(4), 1644–1668. https://doi.org/10.1016/j.clnu.2021.01.028
B. Braun Melsungen AG. (2007). Nutriflex Lipid special emulsion for infusion [Product information; date of last revision September 2007]. Badan Pengawas Obat dan Makanan (Indonesian Food and Drug Authority). https://registrasiobat.pom.go.id/files/assesment-reports/obat_baru/Nutriflex%20Lipid%20Special.pdf https://registrasiobat.pom.go.id/files/assesment-reports/obat_baru/Nutriflex%20Lipid%20Special.pdf
renalcarematters.com content: Parenteral nutrition kidney notes (Nutriflex Lipid Peri): reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Parenteral nutrition kidney notes (Nutriflex Lipid Special): reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Parenteral nutrition kidney notes (Nutriflex Omega Peri): reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.